Supply chains will never be the same as they were pre-pandemic. This is now the “new-normal”
In Conversation
The uniqueness of Synbias lies in the constant innovation that the company is able to implement in its manufacturing processes
By working together, we - the pharmaceutical industry, the health insurers and the FOPH - can create rapid, equal access to reimbursement for innovative drugs at…
Research shows that more than 70 percent of medical decision-making requires some form of diagnostics, yet less than 2 percent of healthcare budgets are allocated for…
There is still change management to be done together with the [Norwegian] hospitals, but the situation is now changing rapidly, with more and more procurement officers,…
We quickly recognized that the mRNA vaccine approach was potentially ideally suited for the rapid development of a vaccine to address COVID-19
Nicolaus Kröger – President, European Society for Blood and Marrow Transplantation (EBMT) (December 2020)

It was critical to build a coalition that is win-win for everyone
It is vital to ensure that we have the right culture and that our employees have a good understanding of the different parts of the business
In the past, public-private collaborations and partnerships were seen negatively in Norway and although we are not yet at the final destination, huge progress has been…
We need to be sure we are not complacent. We have to keep an eye on emerging infections and continue to invest in vaccines and other…
In the fast-developing world of health technologies, especially under the pressure of COVID-19 but already before, there is a need for HTA to be both predictable…
Thomas D. Szucs, European Center of Pharmaceutical Medicine at the University of Basel; Hirslanden Private Hospital, Switzerland; Chairman, Helsana Group

The evolution of genomic medicine needs to be accompanied by the willingness of the hospital system – and to some extent, the payer system as well…